脂质代谢与乳腺癌曲妥珠单抗耐药性机制的相关性研究  

Research progress of lipid metabolism on the mechanism of drug resistance to trastuzumab therapy in breast cancer

作　　者：冯诚天 黄芙蓉(综述) 姜永冬(审校)[1] FENG Chengtian;HUANG Furong;JIANG Yongdong(The First Ward of Mammary Gland,Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院乳腺外科一病区,哈尔滨150081

出　　处：《实用肿瘤学杂志》2023年第2期155-159,共5页Practical Oncology Journal

基　　金：黑龙江省博士后科研基金(编号:LBH-Q20133)。

摘　　要：曲妥珠单抗的出现极大地改善了HER2阳性乳腺癌患者的预后,但仍有一部分患者在治疗过程中出现原发性或继发性的曲妥珠单抗耐药。近年来,曲妥珠单抗的耐药机制越来越受到关注,但耐药现象尚未完全阐明。脂质代谢作为维持细胞生存的基本生理活动,与HER2阳性乳腺癌细胞产生靶向治疗耐药性有着密切的关系,有望成为治疗曲妥珠单抗耐药的新靶点。本文就脂质代谢与曲妥珠单抗耐药性机制之间的相关性作一综述。The emergence of trastuzumab has greatly improved the prognosis of patients with HER2-positive breast cancer,but some patients still develop primary or secondary trastuzumab resistance during treatment.In recent years,the drug resistance mechanism of trastuzumab has attracted more and more attention,but the drug resistance phenomenon has not been fully elucidated.Lipid metabolism,as a basic physiological activity to maintain cell survival,is closely related to the resistance of HER2-positive breast cancer cells to targeted therapy,and is expected to become a new target for the treatment of trastuzumab resistance.This article reviews the relationship between lipid metabolism and the mechanism of trastuzumab resistance.

关 键 词：脂质代谢 HER2阳性乳腺癌 耐药性 

分 类 号：R737.9[医药卫生—肿瘤]